John Raymond Go

John Raymond Go

Auto-generated profile, based on publicly available information

John Raymond Go

Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
CCCristina Corsini Campioli
Cristina Corsini Campioli
NANatalia E Castillo Almeida
Natalia E Castillo Almeida
JOJohn C O’horo
John C O’horo
DCDouglas Challener
Douglas Challener
JGJohn Raymond Go
John Raymond Go
MSM Rizwan Sohail
M Rizwan Sohail
Nocardial brain abscesses are rare, and published literature describing brain abscesses due to Nocardia species is limited to individual case reports or small series. We report one of the largest contemporary retrospective studies describing risk factors, diagnostic evaluation, management, and outcomes of nocardial brain abscess. Retrospective review of all adults with brain abscess due to culture-confirmed Nocardia species at our institution between January 1, 2009, and June 30, 2020. Overall, 24 patients had nocardial brain abscesses during the study period. The median age at presentation was 64 years, and 62.5% were immunocompromised. Pulmonary and cutaneous infections were the most common primary sites of nocardial infection. All 24 patients had magnetic resonance imaging performed, and the frontal lobe was the most commonly involved. The most common organism isolated was Nocardia farcinica, followed by Nocardia wallacei and Nocardia cyriacigeorgica. Thirteen patients were managed with antimicrobial therapy alone, while 11 had both medical and surgical management. In all patients, dual therapy was recommended for the initial 6 weeks of treatment, and 22 patients received at least 1 oral agent as part of their final antibiotic regimen, predominantly trimethoprim-sulfamethoxazole and linezolid. Fourteen patients achieved complete clinical and radiographic resolution of infection. Nocardia is an important cause of brain abscess in the immunocompromised host. Early diagnostic and therapeutic aspiration may help health care providers confirm the diagnosis, choose an appropriate antimicrobial regimen, and achieve source control.

18 December 2021 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
JGJohn Raymond Go
John Raymond Go
DCDouglas W. William Challener
Douglas W. William Challener
CCCristina Corsini Campioli
Cristina Corsini Campioli
MSMuhammad Rizwan Sohail
Muhammad Rizwan Sohail
RPRaj Palraj
Raj Palraj
OAOmar M. Abu-Saleh
Omar M. Abu-Saleh
Clinical significance of a single positive blood culture bottle (SPBCB) with Staphylococcus aureus is unclear. We aimed to assess the significance of an SPBCB by looking at the associated outcomes. We performed a retrospective, multicenter study of patients with an SPBCB with S aureus using data collected from both electronic health records and the clinical microbiology laboratory. Overall, 534 patients with S aureus bacteremia were identified and 118 (22.1%) had an SPBCB. Among cases with an SPBCB, 106 (89.8%) were classified as clinically significant whereas 12 (10.2%) were considered contaminated or of unclear significance. A majority (92.4%) of patients received antibiotic therapy, but patients with clinically significant bacteremia were treated with longer courses (25.9 vs 5.7 days, P < .001). Significant differences in both frequency of echocardiography (65.1% vs 84.6%, P < .001) and infective endocarditis diagnosis (3.8% vs 14.2%, P = .002) were seen in those with an SPBCB compared to those with multiple positive bottles. A longer hospital length of stay and higher 90-day, 6-month, and 1-year mortality rates were seen in patients with multiple positive blood culture bottles. An SPBCB with S aureus was common among our patients. While this syndrome has a more favorable prognosis as compared to those with multiple positive blood cultures, clinicians should remain concerned as it portends a risk of infective endocarditis and mortality.

16 February 2021 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
CCCristina Corsini Campioli
Cristina Corsini Campioli
JGJohn Raymond Go
John Raymond Go
OAOmar M. Abu-Saleh
Omar M. Abu-Saleh
DCDouglas Challener
Douglas Challener
ZYZachary A Yetmar
Zachary A Yetmar
DODouglas R Osmon
Douglas R Osmon
Cefazolin is commonly used as an alternative to antistaphylococcal penicillins (ASPs) in treating methicillin-susceptible Staphylococcus aureus (MSSA) infections; however, no study has compared these agents in MSSA spinal epidural abscess (SEA). We describe our experience in managing MSSA SEA and compare the clinical efficacy of cefazolin with ASPs. This retrospective multicenter study reviewed 79 adult patients diagnosed with SEA between January 2006 and July 2020 using data collected from electronic health records and clinical microbiology laboratory databases. Forty-five patients received cefazolin, while 34 received ASPs. The total antibiotic duration was longer in the ASPs group but not statistically significant. There were no significant differences in treatment failure at week 6 vs week 12, 30-day vs overall mortality, or in 90-day recurrence rates between the treatment groups. Cefazolin was equally as effective as ASPs, and our findings suggest that it can be an alternative to ASPs in the treatment of MSSA SEA.

1 February 2022 in Journal of Infection
Verified
Journal Article
Closed access
SCSupavit Chesdachai
Supavit Chesdachai
ZYZachary A Yetmar
Zachary A Yetmar
Hussam TabajaHussam Tabaja
Hussam Tabaja
ICIsin Y. Comba
Isin Y. Comba
JGJohn R. Go
John R. Go
OAOmar M. Abu-Saleh
Omar M. Abu-Saleh

28 August 2022 in Diagnostic Microbiology and Infectious Disease
Verified
Journal Article
Closed access
JGJohn Raymond Go
John Raymond Go
LBLarry M. Baddour
Larry M. Baddour
BLBrian D. Lahr
Brian D. Lahr
MSM. Rizwan Sohail
M. Rizwan Sohail
RPRaj Palraj
Raj Palraj

18 November 2020 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
PDF file
JGJohn Raymond Go
John Raymond Go
NWNancy L. Wengenack
Nancy L. Wengenack
OSOmar M. Abu Saleh
Omar M. Abu Saleh
CCCristina Corsini Campioli
Cristina Corsini Campioli
SDSharon M. Deml
Sharon M. Deml
JWJohn W. Wilson
John W. Wilson
Mycobacterium septicum is a rarely identified nontuberculous mycobacterium capable of causing infections in both healthy and immunocompromised individuals. Only a few cases of M. septicum infections have been reported, which makes recognizing corresponding clinical disease more challenging for clinicians. Antimicrobial susceptibility profiles for this organism are not well described, and corresponding optimal therapeutic regimens have not been established. We report a tertiary care center9s experience with M. septicum from 2014 to 2020. Twelve adult patients with positive cultures for M. septicum were identified. Most cases were identified from sputum samples of individuals with underlying lung disease. Most cases involving M. septicum isolation in culture were not felt to be clinically significant. Two cases were considered possible infections while only one case was considered a definite infection that required antimicrobial treatment. All M. septicum isolates were susceptible in vitro to amikacin, ciprofloxacin, imipenem, linezolid, moxifloxacin, and trimethoprim-sulfamethoxazole. Isolates were universally resistant to clarithromycin and doxycycline. The isolation of M. septicum in culture is uncommon and requires clinical correlation to determine its clinical relevance and need for treatment. Susceptibility testing should be performed to guide therapy.